Synthesis of triazolotriazine derivatives as c-Met inhibitors

被引：6

作者：

Guo, Yuting ^{[1
,3
]}

Peng, Xia ^{[2
]}

Ji, Yinchun ^{[2
]}

Zhang, Yitong ^{[2
,3
]}

Ding, Jian ^{[2
,3
]}

Zhan, Zhengsheng ^{[1
]}

Ai, Jing ^{[2
,3
]}

Duan, Wenhu ^{[1
,3
]}

机构：

[1] Chinese Acad Sci, Shanghai Inst Mat Med, Dept Med Chem, 555 Zu Chong Zhi Rd, Shanghai 201203, Peoples R China

[2] Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, State Key Lab Drug Res, 555 Zu Chong Zhi Rd, Shanghai 201203, Peoples R China

[3] Univ Chinese Acad Sci, 19A Yuquan Rd, Beijing 100049, Peoples R China

来源：

MOLECULAR DIVERSITY | 2021年 / 25卷 / 02期

基金：

中国国家自然科学基金;

关键词：

Receptor tyrosine kinase; c-Met; Triazolotriazine; SAR; Cellular potency; GROWTH-FACTOR RECEPTOR; KINASE INHIBITOR; HIGHLY POTENT; DISCOVERY; IDENTIFICATION; PROTOONCOGENE; CABOZANTINIB; METASTASIS; VOLITINIB; PATHWAY;

D O I：

10.1007/s11030-020-10067-5

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Receptor tyrosine kinase c-Met is an important antitumor drug target. Triazolotriazine analogues2-10were prepared efficiently and evaluated the enzymatic and cellular c-Met activities. Brief structure-activity relationships of triazolotriazine core and CF2-quinoline part were investigated, leading to the discovery of compound8with nanomolar enzymatic c-Met activity, and subnanomolar MKN45 and EBC-1 cellular potencies. The proposed binding model of 8 and c-Met unraveled that two canonical hydrogen bonds and a pi-pi stacking interaction formed between the inhibitor and the ATP binding site of c-Met kinase domain, which accounted for its potent c-Met activities. [GRAPHICS] .

引用

页码：839 / 846

页数：8

共 28 条

[1]

BELLUSCI S, 1994, ONCOGENE, V9, P1091

[2] Targeting the Hepatocyte Growth Factor-cMET Axis in Cancer Therapy [J].

Blumenschein, George R., Jr. ;

Mills, Gordon B. ;

Gonzalez-Angulo, Ana M. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (26) :3287-3296

[3] IDENTIFICATION OF THE HEPATOCYTE GROWTH-FACTOR RECEPTOR AS THE C-MET PROTOONCOGENE PRODUCT [J].

BOTTARO, DP ;

RUBIN, JS ;

FALETTO, DL ;

CHAN, AML ;

KMIECIK, TE ;

VANDEWOUDE, GF ;

AARONSON, SA .

SCIENCE, 1991, 251 (4995) :802-804

[4] Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress [J].

Cui, J. Jean .

JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (11) :4427-4453

[5] Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer [J].

Cui, J. Jean ;

McTigue, Michele ;

Nambu, Mitchell ;

Tran-Dube, Michelle ;

Pairish, Mason ;

Shen, Hong ;

Jia, Lei ;

Cheng, Hengmiao ;

Hoffman, Jacqui ;

Le, Phuong ;

Jalaie, Mehran ;

Goetz, Gilles H. ;

Ryan, Kevin ;

Grodsky, Neil ;

Deng, Ya-Li ;

Parker, Max ;

Timofeevski, Sergei ;

Murray, Brion W. ;

Yamazaki, Shinji ;

Aguirre, Shirley ;

Li, Qiuhua ;

Zou, Helen ;

Christensen, James .

JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (18) :8091-8109

[6] Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK) [J].

Cui, J. Jean ;

Tran-Dube, Michelle ;

Shen, Hong ;

Nambu, Mitchell ;

Kung, Pei-Pei ;

Pairish, Mason ;

Jia, Lei ;

Meng, Jerry ;

Funk, Lee ;

Botrous, Iriny ;

McTigue, Michele ;

Grodsky, Neil ;

Ryan, Kevin ;

Padrique, Ellen ;

Alton, Gordon ;

Timofeevski, Sergei ;

Yamazaki, Shinji ;

Li, Quhua ;

Zou, Helen ;

Christensen, James ;

Mroczkowski, Barbara ;

Bender, Steve ;

Kania, Robert S. ;

Edwards, Martin P. .

JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (18) :6342-6363

[7] Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applications [J].

Cui, Jingrong Jean .

EXPERT OPINION ON THERAPEUTIC PATENTS, 2007, 17 (09) :1035-1045

[8] Discovery of a Novel Mode of Protein Kinase Inhibition Characterized by the Mechanism of Inhibition of Human Mesenchymal-epithelial Transition Factor (c-Met) Protein Autophosphorylation by ARQ 197 [J].

Eathiraj, Sudharshan ;

Palma, Rocio ;

Volckova, Erika ;

Hirschi, Marscha ;

France, Dennis S. ;

Ashwell, Mark A. ;

Chan, Thomas C. K. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (23) :20666-20676

[9] Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models [J].

Gavine, Paul R. ;

Ren, Yongxin ;

Han, Lu ;

Lu, Jing ;

Fan, Shiming ;

Zhang, Wei ;

Xu, Wen ;

Liu, Yuan Jie ;

Zhang, Tianwei ;

Fu, Haihua ;

Yu, Yongjuan ;

Wang, Huiying ;

Xu, Shirlian ;

Zhou, Feng ;

Su, Xinying ;

Yin, XiaoLu ;

Xie, Liang ;

Wang, Linfang ;

Qing, Weiguo ;

Jiao, Longxian ;

Su, Weiguo ;

Wang, Q. May .

MOLECULAR ONCOLOGY, 2015, 9 (01) :323-333

[10] Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor [J].

Gherardi, E ;

Youles, ME ;

Miguel, RN ;

Blundell, TL ;

Iamele, L ;

Gough, J ;

Bandyopadhyay, A ;

Hartmann, G ;

Butler, PJG .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (21) :12039-12044

← 1 2 3 →